Pharma pricing pressure is the single biggest variable hanging over Pfizer (PFE), Merck (MRK), and Eli Lilly (LLY) as all three step into the Q1 2026 earnings spotlight this week.
PFE and MRK report Tuesday April 29 pre-market, and LLY follows Wednesday April 30. If you hold any of these names, the calls are about how each team frames three converging policy threats: the expanded Medicare IRA negotiation list, the FDA stance on compounded GLP-1s, and the 2026 PBM rebate reform.
3 Pricing Pressure Themes Across PFE, MRK, and LLY This Week
1. Medicare IRA negotiation list for 2026 and drugs at risk
The Inflation Reduction Act drug price negotiation program is no longer a 2025 talking point. It is live revenue mechanics for Q1 2026.
According to KFF, negotiated prices for the first 10 Part D drugs took effect January 1, 2026, and CMS announced the third negotiation cycle in early 2026 for 2028 implementation.
For PFE, the exposure is concentrated in Eliquis (co-marketed with BMS) and Ibrance, both inside the negotiation cohort. Eliquis is one of Pfizer's largest revenue contributors and the negotiated price now flows through Q1 P&L.
For MRK, Januvia and Janumet are the in-scope assets. The bigger MRK question is forward looking: when does Keytruda hit the negotiation list, and what does the 2025 reconciliation law's broadened orphan drug exclusion mean for that timeline?
For LLY, direct IRA exposure is limited today, but Mounjaro and Zepbound become candidates the moment they cross the seven-year post-approval threshold.
2. Compounding pharmacy threat to LLY and NVO GLP-1 franchise
The compounded GLP-1 story is the second-biggest pricing variable on the LLY call and a direct readthrough to Novo Nordisk (NVO).
According to BioPharma Dive, Novo cut its 2025 sales growth guidance by three percentage points and operating profit guidance by five percentage points, citing compounded knockoffs eroding Wegovy and Ozempic demand in the US.
Lilly's read-through is asymmetric. Tirzepatide (Mounjaro and Zepbound) was never on the FDA shortage list to the same degree as semaglutide, so Lilly's franchise was structurally less exposed to compounders.
That has translated into Zepbound prescription share gains over Wegovy in the US. The question for LLY holders is whether management quantifies the compounder tailwind as it unwinds, or sandbags it into later guidance.
3. PBM rebate reform and implications for pharma margins
The Consolidated Appropriations Act of 2026, signed February 3, includes the most aggressive PBM reform in a decade, and it cuts in two directions for pharma margins.
PBMs are now mandated to pass manufacturer rebates directly through to plans on a quarterly cadence. Starting 2028, Medicare Part D plans must compensate PBMs through flat fees only, eliminating percentage-of-rebate compensation.
The headline read for pharma is positive. Less rebate pressure on list prices means cleaner net pricing and potentially higher gross-to-net realization on contracted volume.
The hidden read is messier. Industry analysts have flagged that list price reductions could deflate the gross-to-net bubble that pharmacies and 340B entities depend on, creating downstream channel disruption that bleeds back into pharma contracting strategy.
If you hold PFE, MRK, or LLY, this week's calls are a chance to recalibrate position sizing across the trio based on which name has the cleanest pricing pressure narrative.
Open Gotrade apps, pull up your three positions side by side, and decide which one earns the next dollar of capital.
3 Questions Pharma Holders Should Track on the Calls
First, does management quantify the IRA hit in dollars, not percentages? PFE and MRK both have negotiated drugs flowing through Q1 P&L for the first time. A clean dollar disclosure on Eliquis, Ibrance, Januvia, and Janumet revenue impact lets you model the run rate. Vague percentage framing is a yellow flag.
Second, does LLY commit to a specific Zepbound prescription share figure post-compounding-shutdown? A management team that gives a hard share number is signalling confidence; one that hedges is signalling concerns about a Zepbound versus Amgen (AMGN) MariTide entrant battle later this year.
Third, do PFE, MRK, and LLY align on PBM reform commentary, or do they diverge? If commentary across the three calls converges on net-positive framing, that is consensus you can trade. If one name signals contracting pain, that is the divergence trade across the trio.
Conclusion
PFE, MRK, and LLY enter Q1 2026 earnings facing the same three-headed pricing pressure setup, but with very different exposure profiles. PFE has the most direct IRA hit flowing through Q1, MRK has the largest forward-looking IRA tail risk in Keytruda, and LLY has the cleanest GLP-1 tailwind as compounding unwinds.
Position sizing across the trio should reflect that asymmetry. Treat this week's calls as a chance to rebalance based on management commentary, not just the EPS line.
Open Gotrade to compare your PFE, MRK, and LLY positions side by side, set price alerts before Tuesday's pre-market open, and use the calls as the trigger to rebalance.
FAQ
When do PFE, MRK, and LLY report Q1 2026 earnings?
Pfizer and Merck both report Tuesday April 29 pre-market, and Eli Lilly reports Wednesday April 30 pre-market.
Which of PFE, MRK, or LLY has the most direct IRA negotiation impact in Q1 2026?
Pfizer, because Eliquis and Ibrance negotiated prices took effect January 1, 2026 and flow through Q1 revenue.
How does the compounded GLP-1 shutdown affect Eli Lilly differently than Novo Nordisk?
Lilly's tirzepatide was never on the FDA shortage list to the same extent as semaglutide, so Lilly was structurally less exposed to compounders and benefits asymmetrically as the loophole closes.
